Clinical Investigation in Effect of Riboflavin Sodium Phosphate on Prevention and Treatment for Patients with Radiotherapy Related Esophagitis

  • Shen, Kang (Oncology Department, Siyang County People's Hospital) ;
  • Huang, Xin-En (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
  • Published : 2015.03.09


Objective: To investigate the clinical effect of riboflavin sodium phosphate on prevention of radiotherapy related esophagitis (RRE). Methods: This retrospective study involved 55 patients with middle and advanced esophageal cancer who were divided into an experimental group of 28 and a control group of 27 patients. Those in the experimental group were treated with riboflavin sodium phosphate combined with conventional symptomatic treatment during radiotherapy; while patients in control group received the latter alone. The incidence and degree of RRE were compared after radiotherapy. Results: The incidences of RRE in experimental and control group were 53.5% and 81.4%, respectively (p<0.05); the incidence of stages III and IV RRE in the experimental group was 17.8%, while in the control group it was 44.4% (p<0.05). Conclusion: Riboflavin sodium phosphate could significantly prevent RRE and reduce the incidence of stage III and IV disease. These results were worthy of further confirmation by randomized controlled trials.



Supported by : Nanjing science committee


  1. Bostrm A, Lindman H, Swartling C, et al (2001). potent corticosteroid (mometasone furoate cream) significantly reduces acute radiation dermatitis:results from a doubleblind randomized study. Radiotheroncol, 59, 257-65.
  2. Choy H, Vokes E (2005). Improving outcomes in the treatment of locally advanced NSCLC with gemcitabine. Lung Cancer, 50, S10-2
  3. Gatzioufas Z, Seitz B (2010). Riboflavin-UVA treatment for nonhealing ulcers of the cornea. J Refract Surg, 26, 312.
  4. Huang XE, Cao J, Qian ZY, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev, 15, 8495-7.
  5. Liu J, Huang XE (2014). Efficacy of bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac J Cancer Prev, 15, 10241-4.
  6. Makdoumi K, Mortensen J, Crafoord S (2013). Response to: Evaluation of combined riboflavin and ultraviolet A as an alternative treatment for keratitis. Graefes Arch Clin Exp Ophthalmol, 251, 997.
  7. Qian YD, Xu X, Wang L, et al (2014). Clinical safety of chemotherapy for elderly cancer patients complicated with hypertension. Asian Pac J Cancer Prev, 15, 9875-7.
  8. Russo G, Haddad R , Posner M , et al (2008). Radiation treatment Breaks and ulcerative mucosit is in head and neck cancer. The Oncologist, 13, 886-98.
  9. Serrano A, Frago S, Velazquez-Campoy A, et al (2012). Role of key residues at the flavin mononucleotide (FMN):adenylyltransferase catalytic site of the bifunctional riboflavin kinase/flavin adenine dinucleotide (FAD) Synthetase from Corynebacterium ammoniagenes. Int J Mol Sci, 13, 14492.
  10. Tian GY, Miu M, Huang XE et al (2014). Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev, 15, 8475-8.
  11. Vasilaki A T, McMillan D C, Kinsella J, et al (2010). Relation between riboflavin flavin mononucleotide and flavin adenine dinucleotide concentrations inplasma and red cells in patients with critical illness. Clin Chim Acta, 411, 1750.
  12. Wang L, Huang XE (2014). Clinical study on safety and efficacy of jisaixin (recombinant human granulocyte colony stimulating factor injection manufactured in China) for chinese undergoing chemotherapy. Asian Pac J Cancer Prev, 16, 299-301.
  13. Wojcieszynska D, Hupert-Kocurek K, Guzik U (2012). Flavindependent enzymes in cancer prevention. Int J Mol Sci, 13, 16751
  14. Xiao Y, Liu J, Huang XE, et al (2014). Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Asian Pac J Cancer Prev, 15, 10445-9.
  15. Xuan Z, An Y, Yang D, et al (2013). Exploration of the protection of riboflavin laurate on oral mucositis induced by chemotherapy or radiotherapy at the cellular level: what is the leading contributor. Int J Mol Sci, 14, 4722.

Cited by

  1. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016,
  2. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016,